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Background: Psychopathy and substance use disorders (SUDs) are both characterized
by neurocognitive impairments reflecting higher levels of impulsivity such as
reward-driven decision-making and deficient inhibitory control. Previous studies
suggest that psychopathy may exacerbate decision-making deficits, but it may be
unrelated to other neurocognitive impairments among substance dependent individuals
(SDIs). The aim of the present study was to examine the role of psychopathy
and its interpersonal-affective and impulsive-antisocial dimensions in moderating the
relationships between dependence on different classes of drugs and neurocognitive
domains of impulsivity.
Method: We tested 693 participants (112 heroin mono-dependent individuals, 71 heroin
polysubstance dependent individuals, 115 amphetamine mono-dependent individuals,
76 amphetamine polysubstance dependent individuals, and 319 non-substance
dependent control individuals). Participants were administered the Psychopathy
Checklist: Screening Version (PCL:SV) and seven neurocognitive tasks measuring
impulsive choice/decision-making (Iowa Gambling Task; Cambridge Gambling Task;
Kirby Delay Discounting Task; Balloon Analog Risk Task), and impulsive action/response
inhibition (Go/No-Go Task, Immediate Memory Task, and Stop Signal Task).
Results: A series of hierarchical multiple regressions revealed that the
interpersonal-affective dimension of psychopathy moderated the association between
decision-making, response inhibition and both amphetamine and heroin dependence,
albeit differently. For amphetamine users, low levels of interpersonal-affective traits
predicted poor decision-making on the Iowa Gambling Task and better response
inhibition on the Stop Signal task. In contrast, in heroin users high interpersonal-affective
psychopathy traits predicted lower risk taking on the Cambridge Gambling Task and
better response inhibition on the Go/No-Go task. The impulsive-antisocial dimension of
psychopathy predicted poor response inhibition in both amphetamine and heroin users.
Psederska et al. Psychopathy and Neurocognitive Impulsivity
Conclusions: Our findings reveal that psychopathy and its dimensions had both
common and unique effects on neurocognitive function in heroin and amphetamine
dependent individuals. Our results suggest that the specific interactions between
psychopathy dimensions and dependence on different classes of drugs may lead to
either deficient or superior decision-making and response inhibition performance in
SDIs, suggesting that psychopathy may paradoxically play a protective role for some
neurocognitive functions in specific subtypes of substance users.
Keywords: opioid use disorder, stimulant use disorder, psychopathy, impulsivity, decision-making, response
inhibition
INTRODUCTION
Impulsivity and Substance Use Disorders
Impulsivity, defined as a “predisposition toward rapid,
unplanned reactions to internal or external stimuli without
regards to the negative consequences of these reactions” (1) is
considered a key etiological factor in current conceptualizations
of substance use disorders (SUDs) (2). Deficits in impulse
control are considered both as vulnerability factors that
increase the risk of initiation and maintenance of SUDs
(3, 4), as well as consequences of chronic drug use reflecting
long-term neuroadaptive changes in the brain linked to
specific neurocognitive impairments (5, 6). Despite the strong
associations of impulsivity with SUDs, recent advances in the
literature have drawn attention to the multifactorial nature
of impulsivity and the heterogeneity of SUDs, suggesting
that specific impulsivity dimensions might be differentially
implicated in distinct types of SUDs and in different stages of the
addiction cycle (2, 4, 7).
Impulsivity is a multidimensional construct comprised of a
variety of characteristics reflecting the personality dimensions
of trait impulsivity, as well as a number of neurobehavioral
manifestations, reflecting more fluctuating neurocognitive
dimensions of state impulsivity (8). Trait impulsivity is a
stable personality dimension, widely acknowledged as a
general risk factor for SUDs (9), which is usually measured by
self-report questionnaires such as the Barratt Impulsiveness
Scale-11 [BIS-11; (10)] and the UPPS Impulsive Behavior
Scale [UPPS; (11)]. Trait impulsivity is considered to be
on a continuum between lower, more adaptive levels and
higher, more extreme and maladaptive levels, which feature
prominently in externalizing psychiatric disorders that originate
in childhood and are commonly comorbid with SUDs,
such as attention deficit hyperactivity disorder (ADHD),
oppositional defiant disorder (ODD), conduct disorder, and
antisocial personality disorder (ASPD) (12). In contrast to trait
impulsivity, neurocognitive dimensions of impulsivity are more
fluctuating and dependent on environmental influences and the
current state of the individual (9). Therefore, neurocognitive
domains of impulsivity reflect more imminent risk and are
typically measured in the laboratory with performance-based
computerized tasks.
Neurocognitive impulsivity is additionally subdivided into
two broad domains: impulsive action, involving deficits in
rapid response inhibition (13) and impulsive choice, indicating
deficits in decision-making (14). This distinction is supported
by findings from preclinical studies, which show that impulsive
choice and impulsive action are differentially involved in
distinct stages of the addiction cycle and are mediated by
different neural circuits (15). Impulsive action reflects response
disinhibition and is typically measured by Stop Signal Tasks
[SST; (16)], which examine the ability to cancel an already
initiated motor response, and/or Go/No-Go type of paradigms
(17, 18), measuring the ability to inhibit a prepotent or
dominant behavioral response. Impulsive choice reflects a
reward-driven decision-making style associated with higher risk-
taking and preference for immediate over delayed rewards.
Common tasks of impulsive choice include delay discounting
tasks (19, 20) such as the Monetary Choice Questionnaire
[MCQ; (21)] and simulated gambling tasks measuring sensitivity
to risk and reward, such as the Iowa Gambling Task [IGT;
(22)] measuring decision-making under ambiguity or the
Cambridge Gambling Task [CGT; (23)] and the Balloon
Analog Risk Task [BART; (24)], measuring decision-making
under risk.
Neurocognitive Impulsivity in Substance
Use Disorders
Impairments in neurocognitive impulsivity have long been
implicated in SUDs. Increased response disinhibition and
aberrant decision-making are some of themost common findings
in people with SUDs (23, 25–31). Deficits in neurocognitive
dimensions of impulsivity have gained increased research interest
in the addiction literature as predictors of drug initiation and
poor treatment outcomes. Studies reveal that higher delay
discounting and compromised decision-making are predictive
of post-treatment relapse and can negatively affect one’s ability
to achieve and maintain abstinence from substance use (32–37).
Although response disinhibition on Stop Signal and Go/No-Go
tasks has not been consistently related to treatment retention and
abstinence (34, 35), it has proven to be among the most reliable
predictors of drug use initiation (38–41).
Though individuals with SUDs manifest marked impairments
on virtually all tasks of impulsive choice and impulsive action
(23, 25, 28, 30, 31), recent studies suggest that the type of
deficits demonstrated by individuals with SUDs might also be
affected by the unique properties of the type of substance
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they are using. In line with the precision medicine approach,
current models of addiction emphasize the increasing need
for identifying substance-specific personality and neurocognitive
risk profiles that reflect the specific psychopharmacological
effects of different classes of drugs and the distinct positive and
negative reinforcement mechanisms implicated in different types
of SUDs (2, 42, 43). Research increasingly reveals differences
in neurocognitive dimensions of impulsivity in individuals with
different SUDs, such as stimulant and opioid use disorder.
Although there is accumulating evidence for impaired response
inhibition on impulsive action tasks in individuals with both
stimulant- (28, 31, 44–46) and opioid use disorders (47–49),
studies directly comparing opiate and stimulant users reveal that
stimulant users are characterized by more pronounced response
inhibition deficits than opiate users (31, 50). Studies investigating
impulsive choice in individuals with stimulant and opioid use
disorders have yielded somewhat mixed findings. Some studies
have shown that individuals who preferentially use stimulants
are characterized bymore impulsive decision-making than opiate
users (20, 23, 50, 51), whereas others have failed to find any
performance differences between stimulant and opiate users (31,
52, 53). Machine-learning approaches also reveal that heroin
and amphetamine dependence are characterized by unique
substance-specific neurocognitive impairments (54, 55), with
heroin dependence uniquely predicted by impaired decision-
making, lower risk-taking and intact response inhibition,
whereas amphetamine dependence was predicted by higher delay
discounting and longer reaction times (54).
However, there are several methodological limitations that
limit the conclusions that can be drawn from previous studies
in the field. Polysubstance use is one of the most significant
confounds in studies aiming to dissociate the specific effects
of different classes of drugs. With few exceptions (7, 52, 54),
most studies examining differences in neurocognitive impulsivity
between opiate and stimulant users are based on samples of
polysubstance users whose drug of choice was either opiates or
stimulants (23, 31, 50, 51, 53). Anothermethodological limitation
is related to differences in the length of abstinence across studies
of neurocognitive function in substance users. The majority
of neurocognitive studies on impulsivity explore the effects of
chronic substance use or the effects of early remission (<12
months) (20, 23, 25, 28, 31, 45–47, 50, 51, 53). A few studies have
focused on elucidating the effects of protracted abstinence (>12
months) on different dimensions of neurocognitive impulsivity
(7, 52, 53, 56–58). Differences in the length of abstinence (early
vs. protracted) of participants with SUDs may explain some of
the conflicting findings in the literature, as some neurocognitive
deficits have been shown to recover with abstinence (59–61).
However, few neurocognitive studies in SDIs have addressed
the protracted abstinence stage of the addiction cycle. Finally,
neurocognitive studies often fail to control for the confounding
effects of externalizing traits among people with SUDs, such
as antisocial and psychopathic traits, which are characterized
by similar neurocognitive impairments as those observed in
substance users and may further exacerbate neurocognitive
impairments in SDIs.
Effects of Psychopathy on Neurocognitive
Impulsivity in Substance Users
Psychopathy is a personality disorder characterized by a cluster
of personality and behavioral traits, which fall into two factors.
Factor 1 is characterized by affective (e.g., callousness, lack
of remorse) and interpersonal traits (e.g., manipulativeness,
superficial charm), whereas Factor 2 consists of lifestyle
(e.g., impulsivity, irresponsibility) and antisocial traits (e.g.,
early behavior problems, poor behavioral controls) (62).
This distinction is reflected in the Psychopathy Checklist-
Revised [PCL-R; (63, 64)], the most widely used instrument
for measuring psychopathy, which differentiates between
interpersonal-affective and impulsive-antisocial features of
psychopathy (65, 66), closely resembling the traditional
distinction between primary and secondary psychopathy (67–
69). Studies with the PCL-R reveal that Factor 1 is uniquely
related to lower levels of anxiety and impulsivity, whereas Factor
2 is associated with negative emotionality, impulsivity, and
substance misuse (63, 70, 71).
Psychopathy often co-occurs with SUDs (72–74) and is
associated with a variety of negative outcomes in people with
SUDs, including high treatment attrition, substance use during
treatment, high relapse rates, and increased risk for post-
treatment violent offending (73, 75–77). Studies using machine-
learning approaches reveal that psychopathy is the highest and
the only common predictor of dependence on different classes
of drugs, including heroin, amphetamine, cannabis, nicotine,
and alcohol (54, 55). This suggests that psychopathy may
be an important diagnostic marker for SUDs, regardless of
drug class.
Psychopathy has been associated with impairments in
neurocognitive domains of impulsivity, similar to those observed
in individuals with SUDs. With few exceptions (78, 79), most
studies on impulsive choice in psychopathy have found that
psychopathic individuals manifest suboptimal decision-making,
associated with risky decision-making style and inability to
learn from feedback (80–86). Results are less consistent in
the impulsive action domain, with some studies reporting
higher response disinhibition (87–90), whereas others suggest
intact or even superior response inhibition in psychopathic
individuals (87, 91–93). Inconsistencies across findings may be
explained by the heterogeneity of psychopathy, which has not
been addressed by the majority of studies, which are typically
based on PCL total sum scores that do not take into account
the distinction between interpersonal-affective and impulsive-
antisocial aspects of psychopathy. Focusing exclusively on total
sum scores may lead to conflicting results and conceal important
differential relationships that could deepen our understanding
of psychopathy (94). Studies that have addressed the distinction
between the interpersonal-affective and impulsive-antisocial
dimensions of psychopathy reveal that only Factor 2 (impulsive-
antisocial) is related to impulsive choice, manifested by risky and
less advantageous decision-making (80, 95, 96). With regards to
impulsive action, studies demonstrate that higher scores on PCL-
R Factor 2 and lower scores on Factor 1 were related to poor
response inhibition, suggesting that the affective-interpersonal
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aspects of psychopathy may in fact exert some protective effects
on neurocognitive functioning (97, 98).
Given that both psychopathy and SUDs are associated with
neurocognitive deficits in impulsivity, it has been suggested
that their co-occurrence may increase some impulse-control
deficits in individuals with SUDs (86). In two related studies,
Vassileva et al. (86, 92) examined differences in various
neurocognitive domains of impulsivity in psychopathic and
non-psychopathic mono-substance dependent (“pure”) heroin
users. Findings revealed that comorbid psychopathy exacerbated
decision-making deficits in heroin dependent individuals (86),
but psychopathy was unrelated to delay discounting and
response inhibition in this population (92). However, the role of
psychopathy and its dimensions on neurocognitive functioning
in SUDs is still not well-understood and has been particularly
understudied among individuals dependent on different classes
of drugs and in different stages of the addiction cycle. This is an
important line of inquiry as Factor 1 and 2 may be differentially
related to neurocognitive functioning and impulsivity (99, 100),
which could in turn influence the associations between SUDs and
neurocognitive function.
The aim of the current study was to examine if psychopathy
and its dimensions moderate the relationships between addiction
to different classes of drugs (stimulants vs. opiates) and
neurocognitive domains of impulsivity (impulsive choice and
impulsive action) in substance users in protracted abstinence.
MATERIALS AND METHODS
Participants
Participants were recruited from a larger study on impulsivity
among substance users in Bulgaria via flyers placed at
substance abuse clinics, therapeutic communities, social venues,
as well as through the study’s web page and Facebook page.
Participants were initially screened via telephone on their
medical and substance use histories. All participants had
to meet the following inclusion criteria: (1) age between
18 and 50 years, (2) Raven’s Progressive Matrices (101)
estimated IQ higher than 75; (3) minimum of 8th grade
education; (4) being able to read and write in Bulgarian;
(5) HIV-seronegative status; (6) negative breathalyzer test for
alcohol and negative urine toxicology screen for amphetamines,
methamphetamines, cocaine, opiates, methadone, cannabis,
benzodiazepines, barbiturates, and MDMA. Exclusion criteria
included history of neurological illness, head injury with loss
of consciousness of more than 30min, and history of psychotic
disorders and/or use of antipsychotic medication.
Participants included 693 individuals (64%male), with amean
age of 28.57 years (SD = 7.09). Three hundred seventy-four
participants (74.1% male) had a DSM-IV history of substance
dependence, of whom 183 were dependent on heroin (77%
male) (112 mono-dependent, 71 polysubstance dependent) and
191 were dependent on amphetamines (71.2% male) (115
mono-dependent, 76 polysubstance dependent). The majority
of participants with a history of substance dependence (69%)
were in protracted abstinence at the time of testing (i.e., full
sustained remission for more than 12 months by DSM-IV
criteria) (102). In addition, 319 participants (53% male) had no
past or current history of abuse or dependence on any substance,
of whom 62 were non-substance dependent siblings of heroin
users (44% male), and 48 were non-substance dependent siblings
of amphetamine users (40% male).
Procedures
The study was approved by the Institutional Review Boards of
Virginia Commonwealth University and the Medical University
in Sofia on behalf of the Bulgarian Addictions Institute. Subjects
who met inclusion criteria were invited to participate in the
study. All participants gave written informed consent. Abstinence
from alcohol and drug use at the time of testing was verified by
breathalyzer test (Alcoscan AL7000) and urine toxicology screen
for amphetamines, barbiturates, benzodiazepines, cannabis,
cocaine, MDMA, methadone, methamphetamines, and opiates.
All participants were HIV-seronegative, determined by rapid
HIV testing.
Testing was conducted by an experienced team of trained
psychologists at the Bulgarian Addictions Institute in Sofia,
Bulgaria. Data were collected in two sessions of approximately
4 hours each, conducted on two separate days. The assessment
battery included a combination of clinical interviews, self-
report questionnaires and computer-based neurobehavioral
tests. The first session included assessment of substance use
disorders, externalizing psychopathology (e.g., psychopathy,
antisocial personality disorder, ADHD) and intelligence. The
second session included completion of neurocognitive tasks
and self-report measures of externalizing and internalizing
personality traits and disorders (e.g., impulsivity, sensation
seeking, depression, alexithymia). Participants were paid a total
of 80 Bulgarian leva (approximately 50 USD) for participation in
the study.
Measures
Assessment of SUDs and Psychopathy
Substance dependence was assessed with the Structured Clinical
Interview for DSM-IV—Substance Abuse Module [SCID-SAM;
(103)]. The SCID-SAM is a semi-structured clinical interview
designed to determine whether an individual meets criteria for
any SUD (alcohol-, cannabis-, stimulant-, hallucinogen-, opioid
use disorders) according to the DSM-IV (102). Raters assess
the presence of DSM-IV symptoms of substance abuse and
dependence using a three-point scale (0 = not present, 1 =
subthreshold, 2= present). A diagnosis of substance dependence
is made if the participant displayed three (or more) of the
seven substance dependence criteria within a 12-month period.
A symptom count of the number of criteria met for heroin- and
amphetamine dependence (range 0–7) was used as the main SUD
index in the analyses.
The Psychopathy Checklist: Screening Version [PCL:SV; (104)],
an abbreviated version of the Psychopathy Checklist–Revised
[PCL-R; (63)] was used to measure psychopathy. The PCL:SV
consists of a semi-structured interview, which involves the
assessment of 12 characteristics of psychopathy scored on a
3-point rating scale (0 = absent, 1 = somewhat present, 2 =
definitely present). The PCL:SV is comprised of two factors.
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Factor 1 consists of six items reflecting the interpersonal
and affective characteristics of psychopathy (grandiosity,
manipulativeness, lack of empathy, lack of remorse), while
the remaining six items from Factor 2 measure impulsive
and antisocial behaviors (impulsivity, irresponsibility, poor
behavioral controls, antisocial behavior in adolescence and
adulthood). Items reflecting interpersonal-affective (Factor
1) and impulsive-antisocial (Factor 2) characteristics of
psychopathy were summed to provide a total factor scores
ranging from 0 to 12 points for each psychopathy dimension.
The semi-structured interview for the PCL:SV was conducted
by researchers who were initially trained by the senior author,
who is the author of the Bulgarian version of the PCL-R with
its publisher Multi Health Systems. Additional training and
supervision were further provided by two of the co-authors, who
had participated in formal training workshops led by Robert
Hare, the author of the PCL instruments. In line with earlier
findings (105), the PCL:SV showed good internal consistency for
its total score (α = 0.89) and its two factors (α = 0.78, and α =
0.85) in the current sample.
Neurocognitive Measures of Impulsivity
Measures of Impulsive Choice
Iowa Gambling Task [IGT; (22, 106)] measures decision-
making under uncertainty and requires learning by trial-and-
error. Examinees are presented with four decks of cards and
instructed to select cards to maximize earnings. Decks A and
B are associated with higher rewards but also higher occasional
penalties. Selecting fromDecks C and D yields lower rewards and
lower occasional penalties and is a more advantageous long-term
strategy. The performancemeasure used was the “net score” (IGT
Net score), reflecting the total number of advantageous choices
minus the total number of disadvantageous choices.
Cambridge Gambling Task [CGT; (23)] assesses risky decision-
making, which does not involve learning. Examinees are
presented with 10 boxes colored red or blue and are asked to
guess whether a token is hidden under a red or a blue box. The
ratios of red:blue boxes vary from 1:9 to 9:1 in pseudorandom
order. Participants earn points based on correct performance.
The second phase of the task asks participants to gamble points
based on the confidence of their decisions, by selecting from
an array of bets ranging from 5 to 95% of their earned points,
presented in ascending and descending order. Two performance
indices were used in the analyses: (1) Quality of decision-making
(CGT Quality of decision-making), reflecting the tendency to
bet on the more likely outcome; and (2) Risk taking (CGT Risk
taking), the average number of points scored after the most
probable result has been selected.
Monetary Choice Questionnaire [MCQ; (21)] was used to
measure delay discounting. The questionnaire consists of 27
choices between smaller rewards available on the day of testing
and larger rewards available from 1 week to 6 months in the
future, thereby capturing the tendency to discount rewards that
are delayed in time. The 27 questions were grouped in one
of three categories based on the approximate magnitudes of
the delayed rewards: small ($25–35), medium ($50–60) and
large ($75–85). Analyses utilized the discount-rate parameter k,
calculated using the hyperbolic discount function V = A/[1 +
kD], where V is the value of reward A available at delay D. Two
performance indices were used in the analyses: (1) the overall
temporal discounting rate (i.e., MCQOverall k); (2) the temporal
discounting rate of small magnitude rewards (i.e., MCQ Small
k), which typically has the highest effect sizes from the three
reward magnitudes. We used the log transformed values of both
discounting rates due to the non-normal distribution of MCQ
scores in our sample.
Balloon Analog Risk Task [BART; (24)] is a decision-making
task assessing risk-taking behavior. The participant is presented
with a balloon on the computer screen, along with a balloon
pump, a button for collecting the monetary rewards earned by
pumping the balloon, a temporary bank, and a permanent bank,
where the collected money from each balloon are kept. The task
consists of a total of 30 balloons (trials) presented sequentially
one at a time. At any point during each trial, the examinee
can stop pumping the balloon and click the button to collect
the money, which transfers the earnings accumulated from that
balloon to the permanent bank. In contrast, when a balloon
explodes, the balloon disappears, the money in the temporary
bank is lost for that trial, and the next trial begins. The adjusted
average number of pumps on unexploded balloons (BART
Pumps adjusted average) was used as a measure of risk-taking,
with higher scores indicative of greater risk-taking propensity.
Measures of Impulsive Action
Go/No-Go Task [GNGT; (18)] is a measure of response inhibition
where a series of two-element visual stimuli arrays are presented
on a screen for 500ms and examinees are instructed to
respond when the two elements are identical (“Go”) and to
inhibit responding when the stimuli are discrepant (“No-Go”).
On “No-Go” trials, the position of the inhibitory element is
random, requiring the examinee to scan both elements. Errors
of commission/false alarms (GNG False alarms) were used as an
index of impulsivity in the regression analyses.
Immediate Memory Task [IMT; (17)] is a modified continuous
performance task with higher complexity and sensitivity. A series
of five-digit numbers are shown on a computer screen for 500ms
each, with examinees instructed to respond only if a stimulus is
identical to the preceding one. Errors of commission (i.e., false
alarms), measuring incorrect responding to a non-target stimulus
(IMT Commission errors) were used as an index of impulsivity.
Go Stop Task [SST; (107)] is a stop-signal paradigm, which
presents examinees with a series of five-digit numbers displayed
for 500ms each. Examinees are instructed to respond when
a stimulus is identical to the previous display (“Go”) and
to withhold responding when the stimulus matches, but then
changes color from black to red (“Stop”). Stop signals occurred
at 50, 150, 250, and 350ms intervals after the appearance of
the target “go” stimulus. The performance measure used in the
analyses was the 150ms inhibition ratio (SST 150ms inhibition),
calculated by dividing the failures to inhibit a response on
“Stop trials” by correct detections on “Go trials” at the 150ms
stop-signal delay, which is the index most commonly used in
the literature (107). Higher scores reflect better inhibition or
lower impulsivity.
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Data Analytic Plan
Our main goal was to examine the moderating role of
the two psychopathy dimensions on neurocognitive domains
of impulsivity in heroin and amphetamine users. First,
descriptive statistics and group differences in demographic
characteristics, psychopathy scores and indices of impulsive
choice and impulsive action were performed. Second, a series
of hierarchical multiple regressions were conducted to examine
the moderating role of psychopathy dimensions on the relation
between substance dependence (heroin and amphetamine) and
neurocognitive function (impulsive choice and impulsive action).
All regressions followed the same steps. Step 1 included
biological sex (1 = male, 2 = female), Raven’s estimated IQ,
heroin dependence symptoms, and amphetamine dependence
symptoms. Step 2 added Factor 1 (interpersonal-affective)
and Factor 2 (impulsive-antisocial) of psychopathy. Step 3
included the interaction terms between heroin dependence
and psychopathy factors, and amphetamine dependence and
psychopathy factors. All tests were conducted using an alpha of
0.05. Significant interactions were probed using simple slopes
analysis (108).
RESULTS
Descriptive Statistics and Group
Differences
Group differences in demographic characteristics were examined
using ANOVA. There were significant differences in age [F(2, 689)
= 41.92, p < 0.01], estimated IQ [F(2, 690) = 5.90, p < 0.01]
and years of education [F(2, 687) = 29.46, p < 0.01] across
groups. Tukey’s post-hoc comparisons showed that amphetamine
users were significantly younger than the two other groups,
followed by control participants and heroin users (ps <
0.01) With regards to estimated IQ, both control participants
and amphetamine users scored higher than heroin users (ps
< 0.05). In addition, control participants reported higher
education as compared to both substance dependent groups
(ps < 0.01). Group differences in substance use variables
were examined using Independent Sample t-test. Amphetamine
dependent individuals had lower length of abstinence [t(280)
= 5.10, p < 0.01] and lower symptoms count [t(372) =
9.82, p < 0.01] compared to heroin dependent individuals.
Group differences in indices of psychopathy and neurocognitive
domains of impulsivity were examined using ANOVA followed
by Tukey’s post-hoc comparisons. There were significant group
differences in both interpersonal-affective [F(2, 690) = 173.22,
p < 0.01] and impulsive-antisocial [F(2, 690) = 384.09, p <
0.01] psychopathy dimensions, as well as in psychopathy
total score [F(2, 690) = 343.71, p < 0.01], where heroin
users scored the highest, followed by amphetamine users and
control participants (ps < 0.01). With regards to neurocognitive
indices of impulsivity, groups differed in MCQ Overall k
index of delay discounting [F(2, 653) = 6.66, p < 0.01].
Tukey’s post-hoc comparisons reveal that control participants
had lower discounting rates than heroin users. In addition,
there were group differences in MCQ Small k index of delay
discounting, measuring the temporal discounting rate of small
magnitude rewards [F(2, 653) = 7.66, p < 0.01], where both
amphetamine- and heroin users had higher discounting rates
than control participants (p < 0.05). Please see Tables 1, 2
for participants’ characteristics. Table 1 provides descriptive
statistics and group differences in demographic and substance
use variables. Table 2 provides descriptive statistics and group
differences in indices of psychopathy, impulsive choice, and
impulsive action.
All main analyses were performed using groups of heroin and
amphetamine users, consisting of both mono-dependent, and
polysubstance dependent individuals. For detailed participants
characteristics across groups of heroin- and amphetamine
mono- and polysubstance dependent individuals, please see
Supplementary Tables 1, 2.
Regression Analyses
Impulsive Choice
Iowa Gambling Task (IGT Net score). Step 1 was significant,
F(4, 675) = 7.25, p < 0.001. Higher IGT Net scores were
associated with higher IQ (p < 0.001) and fewer symptoms of
heroin dependence (p = 0.042) and amphetamine dependence
(p = 0.031). Step 2 added the PCL:SV factors to step 1
[F(6, 673) = 5.17, p < 0.001]. Both heroin (p = 0.229) and
amphetamine dependence (p = 0.221) became nonsignificant,
and the psychopathy factors were not significant predictors of
IGT Net score. Step 3 added the interaction term between
psychopathy and substance dependence, [F(10, 669) = 3.61, p <
0.001]. The change in R2 was not significant (p = 0.283). The
interaction between factor 1 and amphetamine was significant (p
= 0.044). Probing this interaction using simple slopes analysis
revealed that amphetamine dependence symptoms were related
to IGT Net score at low levels of Factor 1 (p = 0.031) and
not at high levels of Factor 1 (p = 0.401). Thus, lower Factor
1 scores contribute to the association between amphetamine
dependence symptoms and poor performance on IGT Net score,
whereas higher Factor 1 scores may serve as a buffer in the
association between amphetamine dependence and IGT Net
score performance, as indicated by the nonsignificant difference
(see Figure 1, Table 3).
Cambridge Gambling Task. (1) CGT Quality of decision-
making. Step 1 was significant, F(4, 648) = 5.03, p = 0.001. IQ (p
< 0.001) and biological sex (p = 0.038) were positively related
to CGT Quality of decision-making (p < 0.001). Step 2 [F(6, 646)
= 3.46, p = 0.002] and step 3 were significant [F(10, 642) =
2.13, p= 0.020], but no significant variables emerged. Therefore,
higher IQ and being female was associated with higher quality of
decision-making (see Table 3). (2) CGT Risk taking. Step 1 was
significant, F(4, 648) = 8.53, p< 0.001. Being male (p< 0.001) and
higher amphetamine dependence symptoms (p = 0.028) were
related to higher CGT Risk taking scores. Step 2 was significant
[F(6, 646) = 6.30, p< 0.001] but no new variables were significant.
Step 3 was significant [F(10, 642) = 4.67, p < 0.001] and R
2 change
approached significance (p = 0.071). The interaction between
heroin dependence and PCL:SV Factor 1 was significant (p =
0.009). The simple slopes analysis was significant for high levels
of Factor 1 (p = 0.022) but not for low levels (p = 0.177; See
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TABLE 1 | Descriptive statistics and group differences in demographic and substance use variables.
Controls (1) HDIs (2) ADIs (3) p Contrasts
N 319 183 191 – –
Age 28.41 (7.64) 31.96 (5.98) 25.61 (5.57) 0.000 2 > 1 > 3
Biological sex (N/% male) 169 (53%) 141 (77%) 136 (71.2%) 0.000 -
Raven’s estimated IQ 109.19 (13.94) 105.20 (12.87) 109.05 (12.68) 0.003 1, 3 > 2
Years education 14.51 (2.76) 12.86 (2.55) 13.20 (2.18) 0.000 1 > 2, 3
Length of abstinence – 5.67 (5.57) 2.96 (3.00) 0.000 2 > 3
N of symptoms heroin/amphetamine dependence – 6.20 (0.97) 4.74 (1.76) 0.000 2 > 3
HDIs, heroin dependent individuals; ADIs, amphetamine dependent individuals. Values in bold are significant.
TABLE 2 | Descriptive statistics and group differences in indices of psychopathy, decision-making, and response inhibition.
Controls (1) HDIs (2) ADIs (3) p Contrasts
PCL:SV factor 1 1.52 (1.76) 5.45 (2.75) 3.81 (2.75) 0.000 2 > 3 > 1
PCL:SV factor 2 1.81 (2.15) 7.79 (2.74) 6.39 (2.92) 0.000 2 > 3 > 1
PCL:SV total score 3.32 (3.46) 13.25 (4.96) 10.20 (4.98) 0.000 2 > 3 > 1
IGT net score 4.17 (27.52) −1.41 (26.09) 0.58 (26.27) 0.069 –
CGT quality of decision-making 0.89 (0.13) 0.86 (0.14) 0.87 (0.14) 0.073 –
CGT risk taking 0.57 (0.15) 0.59 (0.14) 0.59 (0.15) 0.161 –
MCQ overall k −3.66 (1.55) −3.17 (1.36) −3.35 (1.46) 0.001 2 > 1
MCQ small k −3.18 (1.47) −2.69 (1.29) −2.82 (1.38) 0.001 2, 3 > 1
BART pumps adjusted average 40.06 (12.99) 39.77 (13.20) 41.05 (14.95) 0.622 –
GNG false alarms 15.15 (9.3.) 17.16 (16.67) 17.35 (9.28) 0.063 –
IMT commission errors 38.17 (14.92) 39.47 (14.41) 39.18 (13.12) 0.568 –
SST 150ms inhibition 71.68 (21.34) 71.58 (19.94) 71.79 (21.26) 0.995 –
HDIs, heroin dependent individuals; ADIs, amphetamine dependent individuals. PCL:SV Factor 1, Psychopathy Checklist: Screening Version Factor 1; PCL:SV Factor 2, Psychopathy
Checklist: Screening Version Factor 2; PCL:SV Total score, Psychopathy Checklist: Screening Version Total score; MCQ Overall k, MCQ Overall temporal discounting rate; MCQ Small k,
MCQ Temporal discounting rate of small magnitude rewards; BART Pumps adjusted average, adjusted average number of pumps on unexploded balloons. Values in bold are significant.
FIGURE 1 | The moderating effect of Interpersonal-affective psychopathy dimension on the association between amphetamine dependence and IGT Net score. Low
and high values represent +1.0 and −1.00 SD from the mean.
Figure 2). High PCL:SV Factor 1 scores in individuals with more
symptoms of heroin dependence was associated with less risky
decision-making (see Table 3).
Monetary Choice Questionnaire. (1) MCQ Overall k. Step 1
was significant, F(4, 660) = 5.78, p < 0.001. Biological sex (p =
0.036) and IQ (p = 0.001) were related to MCQ Overall k. Step 2
Frontiers in Psychiatry | www.frontiersin.org 7 June 2021 | Volume 12 | Article 660810
Psederska et al. Psychopathy and Neurocognitive Impulsivity
TABLE 3 | Substance use and psychopathy as predictors of (1) IGT Net score, (2) CGT Quality of decision-making, and (3) CGT Risk taking.
IGT net score CGT quality of decision-making CGT risk taking
B SE B β 1R2 B SE B β 1R2 B SE B β 1R2
Step 1 0.04** 0.03** 0.05**
Biological sex −2.13 2.15 −0.04 0.02 0.01 0.08* −0.06 0.01 −0.20***
Raven’s estimated IQ 0.34 0.08 0.17*** 0.00 0.00 0.14*** 0.00 0.00 −0.02
Heroin −2.13 1.05 −0.08* −0.01 0.01 −0.04 0.00 0.01 −0.02
Amphetamine −2.21 1.02 −0.08* 0.00 0.01 −0.01 0.01 0.01 0.09*
Step 2 0.00 0.00 0.01
Biological sex −1.88 2.32 −0.03 0.02 0.01 0.08 −0.06 0.01 −0.18
Raven’s estimated IQ 0.33 0.08 0.16*** 0.00 0.00 0.13** 0.00 0.00 −0.01
Heroin −1.63 1.35 −0.06 0.00 0.01 −0.01 −0.01 0.01 −0.08
Amphetamine −1.54 1.26 −0.06 0.00 0.01 0.01 0.01 0.01 0.03
Factor 1 1.78 1.60 0.07 0.00 0.01 0.01 0.00 0.01 0.02
Factor 2 −2.41 1.79 −0.09 −0.01 0.01 −0.05 0.02 0.01 0.10
Step 3 0.01 0.00 0.07
Biological sex −2.20 2.33 −0.04 0.02 0.01 0.07 −0.05 0.01 −0.17
Raven’s estimated IQ 0.34 0.08 0.17 0.00 0.00 0.13** 0.00 0.00 −0.01
Heroin −2.29 1.55 −0.09 0.00 0.01 0.00 −0.01 0.01 −0.03
Amphetamine −1.23 1.34 −0.05 0.00 0.01 0.00 0.00 0.01 0.02
Factor 1 0.83 1.68 0.03 0.00 0.01 0.01 0.01 0.01 0.06
Factor 2 −1.65 1.82 −0.06 −0.01 0.01 −0.05 0.01 0.01 0.08
Heroin X factor 1 0.65 1.51 0.02 0.00 0.01 −0.01 −0.02 0.01 −0.15*
Heroin X factor 2 0.76 1.74 0.03 0.00 0.01 −0.01 0.01 0.01 0.04
Amphetamine X factor 1 2.93 1.45 0.11* 0.00 0.01 0.02 −0.01 0.01 −0.05
Amphetamine X factor 2 −2.06 1.62 −0.07 0.00 0.01 0.00 0.01 0.01 0.04
Biological sex, Male (1), Female (2); *p < 0.05; **p < 0.01; ***p < 0.001.
FIGURE 2 | The moderating effect of Interpersonal-affective psychopathy dimension on the association between heroin dependence and CGT Risk taking. Low and
high values represent +1.0 and −1.00 SD from the mean.
[F(6, 658) = 4.71, p = 0.001] and step 3 were significant [F(10, 654)
= 3.32, p < 0.001], but no significant predictors emerged.
Therefore, being male and having lower IQ were related to higher
delay discounting (see Table 4). (2) MCQ Small k. Step 1 was
significant, F(4, 660) = 5.71, p < 0.001. Lower IQ (p = 0.004) and
higher amphetamine dependence symptoms (p = 0.042) were
associated with MCQ Small k. Step 2 [F(6, 658) = 4.03, p = 0.001]
and step 3 were significant [F(10, 654) = 3.16, p = 0.001], but no
significant predictors emerged (see Table 4).
Balloon Analog Risk Task (BART Pumps adjusted average).
Results of the hierarchical regression analyses with BART
Pumps adjusted average are displayed in Table 4. Step 1, which
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TABLE 4 | Substance use and psychopathy as predictors of (1) MCQ Overall k, (2) MCQ Small k, and (3) BART Pumps adjusted average.
MCQ overall k MCQ small k BART pumps adjusted average
B SE B β 1R2 B SE B β 1R2 B SE B β 1R2
Step 1 0.03*** 0.03*** 0.03**
Biological sex −0.25 0.12 −0.08* −0.22 0.12 −0.08** −1.70 1.09 −0.06
Raven’s estimated IQ −0.01 0.00 −0.13** −0.01 0.00 −0.11 0.15 0.04 0.15***
Heroin 0.09 0.06 0.06 0.10 0.06 0.07 0.11 0.54 0.01
Amphetamine 0.09 0.06 0.06 0.11 0.06 0.08* 0.29 0.52 0.02
Step 2 0.01 0.00 0.00
Biological sex −0.15 0.13 −0.05 −0.18 0.12 −0.06 −1.65 1.18 −0.06
Raven’s estimated IQ −0.01 0.00 −0.11** −0.01 0.00 −0.11** 0.15 0.04 0.15***
Heroin −0.02 0.08 −0.01 0.05 0.07 0.03 −0.14 0.69 −0.01
Amphetamine 0.00 0.07 0.00 0.06 0.07 0.05 0.03 0.64 0.00
Factor 1 0.08 0.09 0.05 0.01 0.08 0.00 −0.36 0.81 −0.03
Factor 2 0.13 0.10 0.09 0.09 0.10 0.07 0.76 0.91 0.06
Step 3 0.01 0.01 0.00
Biological sex −0.15 0.13 −0.05 −0.18 0.12 −0.06 −1.51 1.19 −0.05
Raven’s estimated IQ −0.01 0.00 −0.11** −0.01 0.00 −0.10* 0.15 0.04 0.15***
Heroin 0.03 0.09 0.02 0.07 0.09 0.05 0.05 0.79 0.00
Amphetamine 0.03 0.08 0.02 0.11 0.07 0.08 −0.01 0.68 0.00
Factor 1 0.09 0.09 0.06 0.02 0.09 0.02 −0.01 0.85 0.00
Factor 2 0.11 0.10 0.08 0.07 0.10 0.05 0.48 0.93 0.04
Heroin X factor 1 −0.02 0.08 −0.02 −0.05 0.08 −0.04 −0.32 0.77 −0.02
Heroin X factor 2 −0.10 0.10 −0.06 −0.05 0.09 −0.03 −0.18 0.89 −0.01
Amphetamine X factor 1 0.01 0.08 0.01 −0.01 0.08 0.00 −0.96 0.73 −0.07
Amphetamine X factor 2 −0.12 0.09 −0.08 −0.15 0.09 −0.10 0.49 0.82 0.03
Biological sex = Male (1), Female (2); *p < 0.05; **p < 0.01; ***p < 0.001.
included biological sex, IQ, heroin dependence symptoms, and
amphetamine dependence symptoms was significant, F(4, 686)
= 4.33, p = 0.002. IQ was positively related to BART Pumps
adjusted average (p < 0.001). Step 2 added the psychopathy
factors, which was significant, F(6, 684) = 29.99, p = 0.007.
However, no new significant variables emerged. Step 3 added
the interaction between the psychopathy factors and substance
dependence, which was significant, F(10, 680) = 2.02, p= 0.029 but
no interaction terms were significant. In sum, the only predictor
to emerge was IQ, which was positively associated with risk
taking (BART Pumps adjusted average).
Impulsive Action
Go/No-Go Task (GNG False alarms). Step 1 was significant,
F(4, 683) = 6.72, p < 0.001. Higher GNG False alarms were
associated with lower IQ (p = 0.001) and higher amphetamine
dependence symptoms (p< 0.001). Step 2 added the psychopathy
factors to step 1 [F(6, 681) = 5.52, p < 0.001]. Amphetamine
dependence (p = 0.221) became non-significant, and Factor
2 was positively associated with GNG False alarms (p =
0.021). Step 3 added the interaction terms between psychopathy
and substance dependence [F(10, 677) = 5.04, p < 0.001]
but the change in R2 was not significant (p = 0.573). The
interactions between heroin dependence and Factor 1 (p =
0.003) and Factor 2 (p < 0.001) were significant. In addition,
the interaction between amphetamine dependence and Factor
2 was significant (p = 0.041). Each of these interactions were
probed using simple slopes analysis, which revealed that GNG
False alarms performance was related to high heroin dependence
symptoms for those with high Factor 1 scores (p = 0.031; See
Figure 3; Table 5).
Simple slopes analysis testing the interaction between heroin
dependence and Factor 2 indicated that higher GNG False alarms
scores were related to high heroin dependence symptoms at high
Factor 2 scores (p= 0.010), while lower GNG False alarms scores
were related to high heroin at low Factor 2 scores (p = 0.007;
see Figure 4).
The simple slopes model for the interaction term between
amphetamine and Factor 2 suggests that higher scores of GNG
False alarms are related to high amphetamine dependence
symptoms at high factor 2 scores (see Figure 5).
Immediate Memory Task (IMT Commission errors). Step 1
was significant, F(4, 693) = 6.16, p < 0.001, which showed that
higher IMT Commission errors were associated with lower IQ
(p = 0.001). Step 2 [F(6, 691) = 4.60, p < 0.001] and step 3
were significant [F(10, 687) = 3.21, p < 0.001], but no significant
variables emerged. Thus, lower IQ was related to higher errors of
commission (see Table 5).
Go Stop Task (SST 150ms inhibition). Table 5 presents the
results of the hierarchical regression. Neither step 1 [F(4, 688) =
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FIGURE 3 | The moderating effect of Interpersonal-affective psychopathy dimension on the association between heroin dependence and GNG False alarms. Low and
high values represent +1.0 and −1.00 SD from the mean.
TABLE 5 | Substance use and psychopathy as predictors of (1) GNG False alarms, (2) IMT Commission errors, and (3) SST 150ms inhibition.
GNG false alarms IMT commission errors SST 150ms inhibition
B SE B β 1R2 B SE B β 1R2 B SE B β 1R2
Step 1 0.04*** 0.03*** 0.04**
Biological sex 1.30 0.93 0.05 −0.86 1.14 −0.03 −4.45 1.69 −0.10
Raven’s estimated IQ −0.12 0.03 −0.13** −0.19 0.04 −0.18*** −0.04 0.06 −0.03**
Heroin 0.65 0.46 0.06 −0.19 0.56 −0.01 0.17 0.83 0.01
Amphetamine 1.60 0.44 0.14*** 0.82 0.54 0.06 0.33 0.80 0.02
Step 2 0.01* 0.00 0.00
Biological sex 1.77 1.01 0.07 −0.14 1.23 −0.01 −5.17 1.83 −0.12
Raven’s estimated IQ −0.10 0.03 −0.12** −0.18 0.04 −0.17*** −0.05 0.06 −0.03**
Heroin −0.16 0.58 −0.01 −0.93 0.71 −0.06 0.44 1.06 0.02
Amphetamine 0.83 0.54 0.07 0.24 0.66 0.02 0.36 0.99 0.02
Factor 1 −0.33 0.68 −0.03 0.61 0.83 0.04 −1.59 1.23 −0.08
Factor 2 1.79 0.77 0.15* 0.88 0.95 0.06 0.85 1.41 0.04
Step 3 0.02** 0.01 0.01
Biological sex 1.83 1.00 0.08 −0.27 1.23 −0.01 −4.84 1.82 −0.11
Raven’s estimated IQ −0.10 0.03 −0.12** −0.17 0.04 −0.16*** −0.05 0.06 −0.03**
Heroin −0.48 0.66 −0.04 −1.08 0.82 −0.08 −0.35 1.21 −0.02
Amphetamine 0.66 0.57 0.06 0.44 0.71 0.03 0.30 1.05 0.01
Factor 1 0.02 0.71 0.00 0.34 0.87 0.02 −0.82 1.29 −0.04
Factor 2 1.76 0.78 0.15* 1.15 0.97 0.08 0.40 1.43 0.02
Heroin X factor 1 −1.93 0.64 −0.17** −0.64 0.80 −0.04 −0.03 1.18 0.00
Heroin X factor 2 2.61 0.74 0.21*** 0.72 0.92 0.05 1.69 1.37 0.07
Amphetamine X factor 1 −0.60 0.61 −0.05 1.20 0.75 0.08 −3.05 1.11 −0.15**
Amphetamine X factor 2 1.40 0.69 0.11* −1.18 0.85 −0.08 2.73 1.26 0.12*
Biological sex = Male (1), Female (2); *p < 0.05; **p < 0.01; ***p < 0.001.
2.11, p = 0.078) nor step 2 [F(6, 686) = 1.68, p = 0.122] were
significant. Step 3, which included the interaction terms between
psychopathy and SUD was significant, F(10, 682) = 2.05, p =
0.027. SST 150ms inhibition was associated with amphetamine
dependence when moderated by Factor 1 (p = 0.006) and Factor
2 (p= 0.031). Factor 1 of psychopathy moderated the association
between amphetamine dependence and SST 150ms inhibition
at low levels of Factor 1 (p = 0.025) but not at high levels of
Factor 1 (p = 0.079; Figure 6). In contrast, Factor 2 moderated
the relation between amphetamine dependence and SST 150ms
inhibition at high levels of Factor 2 (p = 0.032) but not at low
levels of Factor 2 (p = 0.187; Figure 7). Thus, amphetamine
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FIGURE 4 | The moderating effect of Impulsive-antisocial psychopathy dimension on the association between heroin dependence and GNG False alarms. Low and
high values represent +1.0 and −1.00 SD from the mean.
FIGURE 5 | The moderating effect of Impulsive-antisocial psychopathy dimension on the association between amphetamine dependence and GNG False alarms.
Low and high values represent +1.0 and 1.00 SD from the mean.
dependence was related to higher SST 150ms inhibition scores
(i.e., lower impulsivity) when individuals had either low Factor
1 psychopathy scores or high Factor 2 psychopathy scores. This
result highlights that psychopathy factors can differentially serve
as both risk and protective factors for neurocognitive function in
people with amphetamine dependence.
DISCUSSION
The aims of the present study were to examine the effects of
psychopathy and its two dimensions (interpersonal-affective and
impulsive-antisocial) on the relationships between dependence
on different classes of drugs (stimulants and opioids) and
distinct neurocognitive domains of impulsivity (impulsive
choice/decision-making and impulsive action/response
inhibition). Our findings suggest that the two dimensions of
psychopathy had both common and unique moderating effects
on decision-making and response inhibition in individuals
dependent on stimulants or opiates.
Within the domain of impulsive choice, our results
demonstrate that the interpersonal-affective dimension of
psychopathy (Factor 1) moderates the associations between
quality of decision-making, risk-taking, and dependence in a
similar manner for opiates and stimulants. Specifically, lower
risk taking on the CGT was predicted by the combination
of more symptoms of heroin dependence and high scores
on the interpersonal-affective dimension of psychopathy
(PCL:SV Factor 1). With few exceptions (78, 79), previous
studies conducted separately with psychopathic individuals
(80–84, 95) and with opioid dependent individuals (47–
49, 56, 61, 109) report that both groups are characterized
by riskier and less advantageous decision-making. To our
knowledge, only one study to date has examined the effects
of co-occurring psychopathy and opioid dependence on
decision-making. Vassileva et al. (86) reported that psychopathic
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FIGURE 6 | The moderating effect of Interpersonal-affective psychopathy dimension on the association between amphetamine dependence and SST 150ms
inhibition. Low and high values represent +1.0 and −1.00 SD from the mean.
FIGURE 7 | The moderating effect of Impulsive-antisocial psychopathy dimension on the association between amphetamine dependence and SST 150ms inhibition.
Low and high values represent +1.0 and −1.00 SD from the mean.
heroin users were characterized by more impaired decision-
making than non-psychopathic heroin users, suggesting that
psychopathy may exacerbate decision-making deficits in
opiate dependent individuals. However, Vassileva et al. (86)
considered psychopathy as a unitary categorical construct
rather than examining its underlying dimensions, therefore it
remained unclear which features of psychopathy were associated
with more impaired decision-making in heroin users and
whether some psychopathic traits may act as a buffer against
disadvantageous and risky decision-making within the context
of opioid addiction. The current study builds upon previous
findings and indicates that the interpersonal-affective features of
psychopathy (Factor 1) may paradoxically play a protective role
and reduce the predisposition toward risky decision-making in
heroin users.
Findings related to the utility of the two psychopathy
dimensions for predicting decision-making in individuals with
amphetamine dependence were somewhat consistent with those
observed among heroin users. Specifically, results revealed
that poor performance on the IGT was predicted by the
combination of more symptoms of amphetamine dependence
and lower scores on the PCL:SV Factor 1, suggesting that
the interpersonal-affective dimension of psychopathy may have
similarly protective effect on decision-making in amphetamine
dependent individuals as it does in heroin dependent individuals.
Interestingly, these results reveal that although the PCL:SV
Factor 1 might have common protective effect on reward-
based decision-making in both opiate and stimulant dependent
individuals, it affects different types of decision-making in heroin
and amphetamine users. Specifically, it was related to decision-
making under ambiguity in amphetamine users, whereas it was
associated with decision-making under risk in heroin users
(58, 110). Therefore, our data suggest that the interpersonal-
affective dimension of psychopathy may be a key factor that may
account for the differential neurocognitive impulsivity profiles
observed in individuals dependent on opiates vs. stimulants.
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Our findings are also consistent with previous studies that
have found that the interpersonal-affective traits of psychopathy
were either unrelated or negatively related to overall decision-
making deficits (80, 95, 96). Unlike previous studies, which
fail to address the unique effects of different dimensions of
psychopathy on decision-making in substance users, our study
was focused on the predictive utility of the two psychopathy
dimensions on the quality of decision-making in different types
of SUDs and on different reward-based decision-making tasks.
Our findings reveal that the interpersonal-affective rather than
the impulsive-antisocial dimension of psychopathy contributes
significantly to intact decision-making in the context of both
opioid and stimulant addictions, and appears to be the key factor
of psychopathy that moderates reward-based decision-making in
individuals with SUDs, regardless of specific drug class.
Within the domain of impulsive action, both the
interpersonal-affective and the impulsive-antisocial dimensions
of psychopathy predicted varying levels of response disinhibition
among individuals dependent on opioids or stimulants. High
scores on the impulsive-antisocial Factor 2 of psychopathy
exacerbated response inhibition deficits on the Go/No-Go task
in both amphetamine- and heroin users. These results are in line
with previous findings from studies conducted separately with
psychopathic individuals (87, 88, 97) and individuals dependent
on stimulants (28, 31, 44–46) and/or opioids (31, 47–49),
suggesting that psychopathy and dependence on both classes
of drugs are related to poor response inhibition. Some studies
on psychopathy have also implicated specifically the impulsive-
antisocial dimension of psychopathy as the key factor underlying
the response inhibition deficits observed in psychopathic
individuals (97, 98, 111). Our findings suggest that increased
levels of impulsive-antisocial psychopathic traits in the context of
addiction may exert additive effects on the already compromised
response inhibition performance in substance users.
In contrast, the interpersonal-affective (Factor 1) dimension
of psychopathy had differential effects on response inhibition
in individuals dependent on opiates vs. stimulants, such that
it exacerbated the response inhibition deficits in amphetamine
dependent individuals, whereas it was related to better response
inhibition in heroin dependent individuals. These results are
in line with studies reporting opposite relationships between
trait impulsivity and neurocognitive impulsivity in heroin
and amphetamine users, where increased trait impulsivity was
associated with worse response inhibition in amphetamine
dependent individuals, but with better response inhibition
in heroin dependent individuals (7). There are reports that
the interpersonal-affective dimension of psychopathy is
related to superior response inhibition among psychopathic
individuals (92, 97, 98). However, research findings to date
are equivocal, with some studies finding positive associations
between interpersonal-affective psychopathic traits and response
inhibition (97, 98), while others have failed to find any
relationships or have reported negative relationships (112, 113).
These conflicting findings may be explained at least partially
by the highly heterogenous samples across studies, e.g.,
criminal offenders (97, 98) vs. students (112, 113). In addition,
inconsistencies between studies could be due to differences in the
assessment of psychopathy [interview-based measures such as
the PCL (97, 98) vs. self-report measures (112, 113)], differences
in the paradigms used to assess response inhibition which may
lead to task-specific effects, and the lack of control for concurrent
SUDs. Our results are limited to opiate and stimulant use
disorders and are focused on the effects of specific combinations
between dependence on different classes of drugs (stimulants
and opioids) and psychopathy dimensions as predictors of
response inhibition. Our findings suggest that drug of choice
may interact uniquely with the interpersonal-affective traits
of psychopathy and result either in better response inhibition
in heroin dependent individuals, or poor response inhibition
in amphetamine dependent individuals. It is important to
note that in the current sample the levels of the interpersonal-
affective dimension of psychopathy were significantly higher
among heroin users than in amphetamine users. Therefore, it
is possible that more pronounced interpersonal-affective traits
can contribute to intact response inhibition, irrespective of the
unique effects of the drug of choice. In addition, our results
suggest that the effects of the PCL:SV Factor 1 on response
inhibition might be task dependent in heroin and amphetamine
users. That is, in amphetamine dependent individuals the
interpersonal-affective psychopathy dimension predicted
diminished ability to cancel an already initiated response as
measured by the Go Stop task, whereas in heroin dependent
individuals it was associated with the ability to inhibit a prepotent
motor response that has not been triggered yet as measured by
the Go/No-Go task.
One surprising finding was that the combination of more
symptoms of amphetamine dependence and higher impulsive-
antisocial features of psychopathy predicted increased inhibitory
control on the Stop Signal Task. This indicates that the impulsive-
antisocial dimension of psychopathy had differential effects
on different tasks of impulsive action in amphetamine users,
facilitating the cancellation of an already triggered prepotent
motor reaction, while exacerbating the difficulties in the ability
to inhibit a dominant response that has not been triggered yet.
These findings are in line with previous studies, which have
suggested that distinct impulsive action tasks (e.g., Go/No-Go,
Stop Signal Tasks) reflect independent cognitive processes, such
as “controlled top-down inhibition” in Stop Signal Tasks vs.
“automatic bottom-up inhibition” in Go/No-Go Tasks (114) that
are mediated by different neural circuits (115–117). Therefore,
our results provide further evidence for the distinction between
different types of neurocognitive impulsivity and the need to
evaluate them separately when examining the specific profiles of
neurocognitive impairments in individuals with different types
of psychopathology.
In summary, our findings suggest that psychopathy
dimensions could play an important role in explaining the
decision-making and response inhibition deficits commonly
observed in substance users, which may have important
clinical implications. First, our results suggest that although
screening for psychopathy is rarely conducted in SUDs treatment
programs, it would provide valuable information, which could
facilitate the development of more personalized interventions
aimed at decreasing the negative treatment outcomes related
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to specific personality and neurocognitive risk factors. For
example, the development and implementation of treatment
interventions targeting the impulsive-antisocial aspects of
psychopathy could be of particular importance when working
with substance users with impaired response inhibition
and higher scores on PCL:SV Factor 2. On the other hand,
detecting higher interpersonal-affective psychopathic traits
could be a resource for improving the quality of decision-
making among substance users. Such interventions could
potentially help reduce relapse rates in substance users, which
are commonly predicted by higher response disinhibition and
impaired decision-making (32–37) and may be significantly
influenced by certain personality characteristics. Nevertheless,
our findings require further investigation and replication in
samples with other types of SUDs (e.g., alcohol-, cannabis
use disorders) and at different stages of the addiction cycle.
In addition, other personality profiles could be tested as
predictors of neurocognitive impairments among substance
users, which could lead to the development of enriched variety of
interventions and therapeutic techniques that are not uniformly
applied among substance users, but are rather tailored to the
individual characteristics of the highly heterogeneous group of
substance users.
LIMITATIONS AND FUTURE DIRECTIONS
A few important limitations need to be considered. First,
our findings are specific to the protracted abstinence stage of
opiate and stimulant addiction and should not be generalized
to other stages of the addiction cycle or to other types of
SUDs. Future studies should examine whether psychopathy
dimensions have similar moderating effects on decision-making
and response inhibition in individuals dependent on other classes
of drugs. Second, our findings were based on the traditional
two-factor model of psychopathy and should be examined
with other models, such as the 4-facet model, which includes
interpersonal, affective, lifestyle and antisocial dimensions (118)
and has been proposed to provide a more sensitive approach
in studying the associations between psychopathy and other
variables (119). Future studies should also examine whether
psychopathy dimensions predict neurocognitive impairments
differently in mono- vs. polysubstance-dependent individuals.
Third, we used a community sample of Bulgarian substance users.
Therefore, caution is warranted in generalizing the conclusions
of our findings before they are replicated cross-culturally.
Another limitation of the current study is that there was no
comprehensive evaluation of co-occurring psychiatric disorders,
that are commonly comorbid with SUDs, such as affective,
neurodevelopmental and personality disorders. Future studies
could examine more thoroughly the possible effects of comorbid
psychopathology on the relationships between psychopathy
dimensions and neurocognitive impulsivity among substance
users. Finally, statistical tests were uncorrected for multiple
comparisons and conducted using an alpha level of 0.05. An
alternative would be to apply the Bonferroni correction, which
may change the interpretation of some results. However, this
method could be overly conservative when conducting multiple
regressions, resulting in a type I error rate much smaller than
the desired alpha, therefore all tests were conducted using an
unadjusted alpha (120).
CONCLUSION
In summary, our results reveal that distinct dimensions of
psychopathy have both common and unique moderating effects
on neurocognitive impulsivity in individuals in protracted
abstinence who are dependent on different classes of drugs
(stimulants vs. opiates). In heroin dependent individuals the
interpersonal-affective features of psychopathy may play a
protective role on both response inhibition and decision-
making, whereas in amphetamine dependent individuals lower
scores on this dimension of psychopathy were associated
with poor decision-making and superior response inhibition.
These findings suggest that the interpersonal-affective features
of psychopathy have similar effects on decision-making
and opposite effects on response inhibition in heroin- and
amphetamine dependent individuals. In contrast, higher scores
on the impulsive-antisocial dimension of psychopathy predicted
response disinhibition in both heroin- and amphetamine
dependent individuals, suggesting that the PCL:SV Factor
2 had common deleterious effects on the ability to inhibit
prepotent motor responses in people with SUDs, regardless of
drug of choice. In addition, impulsive-antisocial psychopathic
traits were uniquely related to increased ability to cancel
an already initiated response in amphetamine dependent
individuals. Overall, our results suggest that not psychopathy per
se, but rather the interaction between its two dimensions
and dependence on specific classes of drugs may lead
to either deficient or superior response inhibition and
decision-making performance in individuals with SUDs in
protracted abstinence.
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